Who are Zolinza's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Treanda, Daunorubicin Hydrochloride, Feximac, Duvyzat, Farydak, BELINOSTAT.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vorinostat.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Zolinza — Competitive Intelligence Brief

Zolinza (VORINOSTAT) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Histone Deacetylase Inhibitor [EPC]. Area: Oncology.

marketed Histone Deacetylase Inhibitor [EPC] Histone deacetylase 6 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Zolinza (VORINOSTAT) — Merck & Co.. Zolinza works by blocking the action of histone deacetylase 6, an enzyme that removes acetyl groups from histones, leading to changes in gene expression.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Zolinza TARGET	VORINOSTAT	Merck & Co.	marketed	Histone Deacetylase Inhibitor [EPC]	Histone deacetylase 6	2006-01-01
Treanda	BENDAMUSTINE	Baxter	marketed	Alkylating Drug	Histone deacetylase 6	2008-01-01
Daunorubicin Hydrochloride	daunorubicin	Meiji Seika Pharma Co., Ltd	marketed	Anthracycline Topoisomerase Inhibitor	Histone deacetylase 6	1979-01-01
Feximac	BUFEXAMAC		marketed	bufexamac	Histone deacetylase 10, Histone deacetylase 6, Arachidonate 5-lipoxygenase
Duvyzat	GIVINOSTAT	Italfarmaco Spa	marketed	Histone Deacetylase Inhibitor [EPC]		2024-01-01
Farydak	PANOBINOSTAT	Secura	marketed	Histone Deacetylase Inhibitor	Histone deacetylase 4	2015-01-01
BELINOSTAT	BELINOSTAT		marketed	Histone Deacetylase Inhibitor [EPC]		2014-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Histone Deacetylase Inhibitor [EPC] class)

· 1 drug in this class
Acrotech Biopharma · 1 drug in this class
Italfarmaco Spa · 1 drug in this class
Merck & Co. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Zolinza — Competitive Intelligence Brief. https://druglandscape.com/ci/vorinostat. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab